Replies to post #430079 on Elite Pharmaceuticals Inc (ELTP)

[namtae]

Your revenue prediction was wrong

[Drugdoctor]

That's quite a nice list you have there. Should be a green check mark by 20 million revenues per quarter, imo. Thanks for the good work you do here.

[Sankarad1]

Exciting information. But how long will it take to clear the list and doing a BO? Does not look like it happens in 12 months.

[Bngo]

Thanks NASDAQ 2020 for keeping us updated on Elite's progress.
Perhaps you can add a line for "Several" drugs in the Pipeline for BE studies.Let's see if Dianne is able to tell us if these several (4+) drugs are blockbuster $Billion drugs like the recent $27B anticoagulant drug that Elite achieved BE with.

[NASDAQ2020]

✅️Elite Pharma (ELTP) Catalyst :✅️

✅️ 1. Cash Flow Positive
✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of Adderall IR $ 421.7 Million from MIKAH
__13. Obtain Full ownership of Adderall XR $ 865 Million from MIKAH
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
X. 24. Generate revenues over $20 million/quarter
X. 25. Generate revenues over $30 million/quarter
__ 26. Generate revenues over $40 million/quarter
__ 27. Generate revenues over $50 million/quarter
__ 28. Double output of manufacturing and packaging facilities —-Imminent
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - Methadone HCL tablets IMS $30 Million
__ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
__ 35. Indian Research and Development agreement
__ 36. Positive BE Study for Concerta CNS Stimulant $1.16 Billion
✅️ ✅️ ✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
__39. Launch Adderall IR in Israel —Imminent
__40. 100 million in yearly revenues —-2025
__41. Generic OxyContin Approval $720 Million
✅️ 42. Accord prevail over Purdue in Generic OxyContin infringement suit - Dec 30, 2024
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf
__43. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__43. Launch generic OxyContin $720 Million
__44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone
__45. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__46. $200 million in yearly revenue
__47. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__48. Undisclosed Mikah ANDA(s)
X. 49. Positive Pivotal BE Undisclosed ANDA JUNE 2025 $27 Billion Market anticoagulant
__50. Generic Concerta Launch $1.16 Billion
__51. DollarLand PPS ——2025
__52. Uplist to NASDAQ exchange
__53. M&A advisory firm selected for buyout
__54. Perform Business Valuation
__55. Develop strategy set for sale of business
__56. Prepare marketing materials for sale
__57. The advisory firm begins to identify and approach potential buyers.
__58. Management teams present the company's strengths and growth potential to interested buyers
__59. Site visits by potential Buyers to inspect and meet management.
__60. Begin Buyout Negotiations
__61. Buyout offer/s
__62. Buyer Identified
__63. Purchase Definitive Agreement
__64. Buyout Vote of Board of Directors
__65. Halt Trading
__66. Shareholder vote on offer
__67. Necessary regulatory approvals are obtained for transfer of ownership
__68. Buyout Closing Completed —$$$$$$$$$$$
__69. Vegas BABY !!!!! 🎰
Bullish

[Bngo]

A major pharmaceutical company can benefit from acquiring a US-based drug manufacturing company in light of impending tariffs in several ways: